Monkeypox is a viral zoonotic disease caused by the monkeypox virus, a member of the orthropox genus in the family poxviridae.
Monkeypox is a viral zoonotic disease caused by the monkeypox virus, a member of the orthropox genus in the family poxviridae. It is a self-limited disease with symptoms lasting from 2 to 4 weeks and can be transmitted by close contact with an infected person’s body fluids, contaminated material such as bedding, lesions, and respiratory droplets. The first human patient was identified in 1970 in the Congo. Since then most cases have been reported from the central and west African regions.
Recently, the World Health Organization declared monkeypox disease as a global health emergency due to a sudden rise in new cases. According to the Center for Disease Control and Prevention (CDC), around 26,208 new cases of the disease have been reported worldwide as of August 2022. The demand for diagnostic testing has increased since the global outbreak. Currently, polymerase chain reaction (PCR) for orthopoxvirus is mostly used for the diagnosis of Monkeypox. However, companies and researchers are working on developing serology-based tests for the diagnosis.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39480
There are several initiatives undertaken by governments at the international and national level to support disease testing. For instance, in June 2022, the U.S. government allowed commercial laboratories to conduct testing in the country. Hence, the domestic diagnostic companies are expanding their capacity nationwide in order to make it more easily accessible for healthcare providers and patients. For instance, on July 6th 2022, Laboratory Corporation of America Holdings started testing for the virus using CDC’s orthopoxvirus test, which is a PCR-based test that detects all the non-small pox orthopoxviruses, including monkeypox. This initiative is expected to boost diagnostic testing in the forecast period.
In Asia Pacific, countries across the region are on high alert for monkeypox, as they reported the first case of the virus with a history of international travel. Singapore and India reported 11 and 8 confirmed cases, respectively. Therefore, governments of respective countries initiated the screening of patients at airports to control the spread of virus. Such measures are driving the demand for testing.
The U.S. reports 7,102 cases as of August 4, 2022, according to the WHO. Even though the testing capacity of the laboratories in the U.S. is plentiful, the demand for testing is rather low. Only 2% of the capacity is currently utilized in the U.S. Moreover, many technicians have been refusing to collect sample from patients who might have monkeypox due to the associate stigma. Travel restrictions, vaccines & mask mandate are some of the mandate protocols to curb the spread of the virus.
Key Players
- Aegis Sciences Corporation
- Laboratory Corporation of America Holdings
- Quest Diagnostics Incorporated
- Sonic Healthcare Limited
- QIAGEN
Market Segmentation
- By Product
- Consumables
- Instruments
- By Technology
- PCR
- Others
- By End-user
- Hospitals & Clinics
- Diagnostic Laboratories
- Others
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39480
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
